PULMONARY PATHOLOGIES AND MANAGEMENT STRATEGIES IN PRIMARY IMMUNODEFICIENCIES

pulmonary_pathologies_kapak

EMERGENCY AND INTENSIVE CARE UNIT MANAGEMENT OF PULMONARY PATHOLOGIES IN PRIMARY IMMUNODEFICIENCIES

Ümmügülsüm Yılmaz Ergün1 Fatih Çölkesen2

1Konya Necmettin Erbakan University, Faculty of Medicine, Department of Immunology and Allergic Diseases, Konya, Türkiye
2Konya Necmettin Erbakan University, Faculty of Medicine, Department of Immunology and Allergic Diseases, Konya, Türkiye

Yılmaz Ergün Ü, Çölkesen F. Emergency and Intensive Care Unit Management of Pulmonary Pathologies in Primary Immunodeficiencies. In: Arslan Ş editor. Pulmonary Pathologies and Management Strategies in Primary Immunodeficiencies. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.153-174.

ABSTRACT

Primary immunodeficiencies (PID) encompass a broad clinical spectrum ranging from recurrent infections to autoimmune and autoinflammatory disorders. This wide range of manifestations contributes to the diversity of complications that may arise in affected individuals. Among organ systems, the pulmonary system is one of the most frequently involved in PIDs. Pulmonary complications can be either infectious or non-infectious in nature. This review focuses on the approach to pulmonary involvement in patients with PIDs from the perspective of emergency and intensive care management, addressing both infectious and non-infectious etiologies.

Keywords: Primary immunodeficiency; Lung disease; Emergency medical service; Intensive care unit

Referanslar

  1. Poli MC, Aksentijevich I, Bousfiha AA, CunninghamRundles C, Hambleton S, Klein C, et al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. Journal of Human Immunity. 2025;1(1):e20250003. [Crossref]
  2. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. The Journal of allergy and clinical immunology. 2015;136(5):1186205.e178. [PubMed]
  3. Buckley RH. Pulmonary complications of primary immunodeficiencies. Paediatric respiratory reviews. 2004;5 Suppl A:S22533. [Crossref]  [PubMed]
  4. Giardino G, Gallo V, Prencipe R, Gaudino G, Romano R, De Cataldis M, et al. Unbalanced Immune System: Immunodeficiencies and Autoimmunity. Front Pediatr. 2016;4:107. atrics [Crossref]  [PubMed]  [PMC]
  5. Walter JE, Farmer JR, Foldvari Z, Torgerson TR, Cooper MA. MechanismBased Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies. The journal of allergy and clinical immunology In practice. 2016;4(6):1089100. [Crossref]  [PubMed]  [PMC]
  6. Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, AlHerz W, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. Journal of clinical immunology. 2022;42(7):150820. [Crossref]  [PubMed]
  7. Grenier PA, Brun AL, Longchampt E, Lipski M, Mellot F, Catherinot E. Primary immunodeficiency diseases of adults: a review of pulmonary complication imaging findings. European radiology. 2024;34(6):414254. [Crossref]  [PubMed]  [PMC]
  8. Ramirez JA, Musher DM, Evans SE, Dela Cruz C, Crothers KA, Hage CA, et al. Treatment of CommunityAcquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. Chest. 2020;158(5):1896911. [Crossref]  [PubMed]  [PMC]
  9. Patrawala M, Cui Y, Peng L, Fuleihan RL, Garabedian EK, Patel K, et al. Pulmonary Disease Burden in Primary Immune Deficiency Disorders: Data from USIDNET Registry. Journal of Clinical Immunology. 2020;40(2):3409. 01900738w [Crossref]  [PubMed]
  10. Azoulay E, Russell L, Van de Louw A, Metaxa V, Bauer P, Povoa P, et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive care medicine. 2020;46:298314. [Crossref]  [PubMed]  [PMC]
  11. Chai J, Han X, Mei Q, Liu T, Walline JH, Xu J, et al. Clinical characteristics and mortality of nontuberculous mycobacterial infection in immunocompromised vs. immunocompetent hosts. Frontiers in Medicine. 2022;9:884446. [Crossref]  [PubMed]
  12. SolerPalacín P, de Gracia J, GonzálezGranado LI, Martín C, RodríguezGallego C, SánchezRamón S, et al. Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management. Respiratory research. 2018;19:113. [Crossref]  [PubMed]  [PMC]
  13. Ozcelik U, Hamutcu Ersu R, Ceyhan M, Kutluk T, Sarıalioglu F, Yel L, et al. Bağişikliği Baskilanmiş Çocuklarda Gelişen Pnömoni Tani Ve Tedavi Uzlaşi Raporu. 2009.
  14. Husmann R, Lehman A, Nelson RW, Pragman AA. Evaluation of Inborn Errors of Immunity Among Patients with Opportunistic Pulmonary Infection. Clinics in chest medicine. 2025;46(1):6175. [Crossref]  [PubMed]
  15. Chan AY, Torgerson TR. Primary immune regulatory disorders: a growing universe of immune dysregulation. Current opinion in allergy and clinical immunology. 2020;20(6):58290. [Crossref]  [PubMed]  [PMC]
  16. Singh A, Jindal AK, Joshi V, Anjani G, Rawat A. An updated review on phenocopies of primary immunodeficiency diseases. Genes & Diseases. 2020;7(1):1225. S2352304219300765 [Crossref]  [PubMed]  [PMC]
  17. RodríguezCréixems M, Muñoz P, Miranda E, Peláez T, Alonso R, Bouza E. Recurrent pneumococcal bacteremia. A warning of immunodeficiency. Archives of internal medicine. 1996;156(13):142934. h [Crossref]  [PubMed]
  18. Marini T, Hobbs SK, Chaturvedi A, KaprothJoslin K. Beyond bronchitis: a review of the congenital and acquired abnormalities of the bronchus. Insights into imaging. 2017;8(1):14153. [Crossref]  [PubMed]  [PMC]
  19. Lehman HK, Karl O, Towe CT, Risma KA. Respiratory infections in patients with primary immunodeficiency. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(3):68391. e1.[Crossref]  [PubMed]
  20. Villafuerte D, Aliberti S, Soni NJ, Faverio P, Marcos PJ, Wunderink RG, et al. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with communityacquired pneumonia. Respirology (Carlton, Vic). 2020;25(5):543-51.[Crossref]  [PubMed]
  21. Woolfrey KG. Pneumonia in adults: the practical emergency department perspective. Emergency Medicine Clinics. 2012;30(2):24970. [Crossref]  [PubMed]  [PMC]
  22. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospitalacquired and Ventilatorassociated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Soci ety of America and the American Thoracic Society. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(5):e61e111. [Crossref]  [PubMed]  [PMC]
  23. Cheng GS, Crothers K, Aliberti S, Bergeron A, Boeckh M, Chien JW, et al. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society. 2023;20(3):34153. nalsATS.2022121019ST [Crossref]  [PubMed]  [PMC]
  24. CuencaEstrella M, Verweij PE, Arendrup MC, ArikanAkdagli S, Bille J, Donnelly JP, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012;18 Suppl 7:9-18.[Crossref]  [PubMed]
  25. Thompson III GR, Young JAH. Aspergillus infections. New England Journal of Medicine. 2021;385(16):1496-509. [Crossref]  [PubMed]
  26. Rossen JWA, Friedrich AW, MoranGilad J. Practical issues in implementing wholegenomesequencing in routine diagnostic microbiology. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018;24(4):35560.[Crossref]  [PubMed]
  27. Franquet T. Highresolution computed tomography (HRCT) of lung infections in nonAIDS immunocompromised patients. European radiology. 2006;16(3):70718. s0033000500081.pdf [Crossref]  [PubMed]
  28. Lionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;67(10):162130. [Crossref]  [PubMed]
  29. Drummond D, Hadchouel A, Petit A, KhenDunlop N, Lozach C, Delacourt C, et al. Strategies for recognizing pneumonia lookalikes. European Journal of Pediatrics. 2022;181(10):356575. [Crossref]  [PubMed]
  30. Tarzi MD, Grigoriadou S, Carr SB, Kuitert LM, Longhurst HJ Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol. 2009;155(2):147. [Crossref]  [PubMed]
  31. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bono mo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobialresistant gramnegative infections. Clinical infectious diseases. 2024:ciae403. [PubMed]
  32. Fishman JA, Marr A, Thorner A. Approach to the immunocompromised patient with fever and pulmonary infiltrates. UptoDate, Waltham, MA. 2022.
  33. Capsoni F, SarziPuttini P, Zanella A. Primary and secondary autoimmune neutropenia. Arthritis research & therapy. 2005;7(5):20814 [Crossref]  [PubMed]  [PMC]
  34. Hranjec T, Rosenberger LH, Swenson B, Metzger R, Flohr TR, Politano AD, et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensivecareunitacquired infection: a quasiexperimental, before and after observational cohort study. The Lancet Infectious diseases. 2012;12(10):77480. [Crossref]  [PubMed]
  35. Murali S, Marks A, Heeger A, Dako F, Febbo J, editors. Pneumonia in the immunocompromised host. Seminars in Roentgenology; 2022: Elsevier. [Crossref]  [PubMed]
  36. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Communityacquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American journal of respiratory and critical care medicine. 2019;200(7):e45e67.[Crossref]  [PubMed]
  37. Gilbert D, Chambers H, Saag M, Pavia A, Boucher H. The Sanford Guide to Antimicrobial Therapy 2022. Sperryville, VA, USA: Antimicrobial Therapy. Inc; 2022.
  38. File TM, Bartlet J, Thomer A. Treatment of communityacquired pneumonia in adults who require hospitalization. Up to Date Wolters Kluwer. 2023;28.
  39. Jernigan JA, Hatfield KM, Wolford H, Nelson RE, Olubajo B, Reddy SC, et al. MultidrugResistant Bacterial Infections in U.S. Hospitalized Patients, 20122017. The New England journal of medicine. 2020;382(14):130919. Moa1914433 [Crossref]  [PubMed]  [PMC]
  40. Torres A, Niederman MS, Chastre J, Ewig S, FernandezVandellos P, Hanberger H, et al. International ERS/ ESICM/ESCMID/ALAT guidelines for the management of hospitalacquired pneumonia and ventilatorassociated pneumonia: Guidelines for the management of hospitalacquired pneumonia (HAP)/ventilatorassociated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). The European respiratory journal. 2017;50(3). key=shareline [Crossref]  [PubMed]
  41. Schmidt GA, Mandel J, Parsons P, Sexton D, Hockberger R, Finlay G. Evaluation and management of suspected sepsis and septic shock in adults. Uptodate Online. 2018:129 [Link]
  42. Klompas M, Branson R, Cawcutt K, Crist M, Eichenwald EC, Greene LR, et al. Strategies to prevent ventilatorassociated pneumonia, ventilatorassociated events, and nonventilator hospitalacquired pneumonia in acutecare hospitals: 2022 Update. Infection control and hospital epidemiology. Infection Control & Hospital Epidemiology. 2022;43(6):68771 . [Crossref]  [PubMed]  [PMC]
  43. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Critical care medicine. 2021;49(11):e1063e143. [PubMed]
  44. Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidimeavibactam versus meropenem in nosocomial in nosocomial pneumonia, including ventilatorassociated pneumonia (REPROVE): a randomised, doubleblind, phase 3 noninferiority trial. The Lancet Infectious diseases. 2018;18(3):28595. [Crossref]  [PubMed]
  45. Kollef MH, Nováček M, Kivistik Ü, RéaNeto Á, Shime N, MartinLoeches I, et al. Ceftolozanetazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECTNP): a randomised, controlled, doubleblind, phase 3, noninferiority trial. The Lancet Infectious diseases. 2019;19(12):1299311. [Crossref]  [PubMed]
  46. Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycosidebased Regimens for the Treatment of Drugresistant Pseudomonas aeruginosa. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;71(2):30410. [Crossref]  [PubMed]
  47. Cisneros JM, RossoFernández CM, RocaOporto C, De Pascale G, JiménezJorge S, FernándezHinojosa E, et al. Colistin versus meropenem in the empirical treatment of ventilatorassociated pneumonia (Magic Bullet study): an investigatordriven, openlabel, randomized, noninferiority controlled trial. Critical care (London, England). 2019;23(1):383. [Crossref]  [PubMed]  [PMC]
  48. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Executive Summary: Management of Adults With Hospitalacquired and Ventilatorassociated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(5):57582. [Crossref]  [PubMed]  [PMC]
  49. Yazdani R, Abolhassani H, Asgardoon M, Shaghaghi M, Modaresi M, Azizi G, et al. Infectious and noninfectious pulmonary complications in patients with primary immunodeficiency disorders. 2017. [Crossref]  [PubMed]
  50. Patrawala M, Cui Y, Peng L, Fuleihan RL, Garabedian EK, Patel K, et al. Pulmonary disease burden in primary immune deficiency disorders: data from USIDNET registry. Journal of clinical immunology. 2020;40:3409. [Crossref]  [PubMed]
  51. Obregon RG, Lynch DA, Kaske T, Newell Jr JD, Kirkpatrick CH. Radiologic findings of adult primary immunodeficiency disorders: contribution of CT. Chest. 1994;106(2):4905. [Crossref]  [PubMed]
  52. MaarschalkEllerbroek LJ, de Jong PA, van Montfrans JM, Lammers JWJ, Bloem AC, Hoepelman AIM, et al. CT Screening for Pulmonary Pathology in Common Variable Immunodeficiency Disorders and the Correlation with Clinical and Immunological Parameters. Journal of Clinical Immunology. 2014;34(6):64254. [Crossref]  [PubMed]
  53. Maglione PJ, Ko HM, Beasley MB, Strauchen JA, CunninghamRundles C. Tertiary lymphoid neogenesis is a component of pulmonary lymphoid hyperplasia in patients with common variable immunodeficiency. Journal of allergy and clinical immunology. 2014;133(2):53542. [Crossref]  [PubMed]  [PMC]
  54. Casal A, Riveiro V, SuárezAntelo J, Ferreiro L, RodríguezNúñez N, Lama A, et al. Pulmonary manifestations of primary humoral deficiencies. Canadian Respiratory Journal. 2022;2022(1):7140919. [Crossref]  [PubMed]  [PMC]
  55. Blackhall V, Asif M, Renieri A, Civitelli S, Kirk A, Jilaihawi A, et al. The role of surgical lung biopsy in the management of interstitial lung disease: experience from a single institution in the UK. Interactive cardiovascular and thoracic surgery. 2013;17(2):2537. [Crossref]  [PubMed]  [PMC]
  56. Jolles S, Carne E, Brouns M, ElShanawany T, Williams P, Marshall C, et al. FDG PETCT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clinical & Experimental Immunology. 2017;187(1):138-45. [Crossref]  [PubMed]  [PMC]
  57. Verbsky JW, Hintermeyer MK, Simpson PM, Feng M, Barbeau J, Rao N, et al. Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. The Journal of allergy and clinical immunology. 2021;147(2):70412.e17. S0091674920310691 [Crossref]  [PubMed]
  58. Baumann U, Routes JM, SolerPalacín P, Jolles S. The lung in primary immunodeficiencies: new concepts in infection and inflammation. Frontiers in immunology. 2018;9:1837. [Crossref]  [PubMed]  [PMC]
  59. Faverio P, De Giacomi F, Sardella L, Fiorentino G, Carone M, Salerno F, et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC pulmonary medicine. 2018;18:113. [Crossref]  [PubMed]  [PMC]
  60. Kershaw CD, Batra K, Torrealba JR, Terada LS. Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases. Respiratory medicine. 2021;183:106400. [Crossref]  [PubMed]  [PMC]
  61. Arevalo C, Nagel DJ. Acute Exacerbations of Interstitial Lung Disease: Evolving Perspectives on Diagnosis and Management. Fibrosis. 2024;2(4):10008 [Crossref]
  62. Alshneikat M, Alnajjar Z, Obeidat O, ALTanjy A, Alsokhni A, Innabi A. Acute Exacerbation of Interstitial Lung Disease: Definitions, Epidemiology, Prognosis and Management. JAPA Academy Journal. 2024;2(1):19. [Crossref]
  63. Charokopos A, Moua T, Ryu JH, Smischney NJ. Acute exacerbation of interstitial lung disease in the intensive care unit. World journal of critical care medicine. 2022;11(1):22-32. [Crossref]  [PubMed]  [PMC]
  64. Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhatt NY, et al. Acute exacerbations of progressivefibrosing inter stitial lung diseases. European respiratory review : an official journal of the European Respiratory Society. 2018;27(150). [Crossref]  [PubMed]  [PMC]
  65. Hayat Syed MK, Bruck O, Kumar A, Surani S. Acute exacerbation of interstitial lung disease in the intensive care unit: Principles of diagnostic evaluation and management. World journal of critical care medicine. 2023;12(3):153-64. [Crossref]  [PubMed]
  66. Martin MJ, Moua T. Mechanical Ventilation and Predictors of InHospital Mortality in Fibrotic Interstitial Lung Disease With Acute Respiratory Failure: A Cohort Analysis Through the Paradigm of Acute Respiratory Distress Syndrome. Critical care medicine. 2020;48(7):9931000. [Crossref]  [PubMed]
  67. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American journal of respiratory and critical care medicine. 2016;194(3):26575. [Crossref]  [PubMed]
  68. Raghu G, RemyJardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American journal of respiratory and critical care medicine. 2022;205(9):e18e47. [PubMed]
  69. Biondini D, Balestro E, Sverzellati N, Cocconcelli E, Bernardinello N, Ryerson CJ, et al. Acute exacerbations of idiopathic pulmonary fibrosis (AEIPF): an overview of current and future therapeutic strategies. Expert review of respiratory medicine. 2020;14(4):40514. [PubMed]
  70. Kulkarni T, Duncan SR. Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat. Current pulmonology reports. 2019;8(4):12330. [PubMed]  [PMC]